Oragenics

OverviewSuggest Edit

Oragenics is focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation Inc., a synthetic biology company. The collaborations allow Oragenics access to Intrexon's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

TypePublic
Founded1996
HQTampa, USMap
Websiteoragenics.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)7(+17%)
Revenue (FY, 2017)$0
Share Price (Sept 2020)$0.7 (-1%)
Cybersecurity ratingBMore

Key People/Management at Oragenics

Alan Joslyn

Alan Joslyn

President and Chief Executive Officer, Director
Charles L. Pope

Charles L. Pope

Director
Michael Sullivan

Michael Sullivan

Chief Financial Officer
Alan Dunton

Alan Dunton

Director
Martin Handfield

Martin Handfield

Senior Vice President of Discovery Research
Robert Koski

Robert Koski

Director
Show more

Oragenics Office Locations

Oragenics has an office in Tampa
Tampa, US (HQ)
4902 Eisenhower Blvd N #125
Show all (1)

Oragenics Financials and Metrics

Oragenics Revenue

USD

Net income (Q2, 2020)

(12.3m)

EBIT (Q2, 2020)

(12.4m)

Market capitalization (22-Sept-2020)

42.2m

Closing stock price (22-Sept-2020)

0.7

Cash (30-Jun-2020)

9.6m

EV

33.4m
Oragenics's current market capitalization is $42.2 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

1.4m1.3m1.0m939.9k1.2m

Revenue growth, %

(9%)25%(100%)

Cost of goods sold

713.6k878.5k343.4k369.6k481.7k

Gross profit

730.8k453.3k688.9k570.3k694.1k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

347.6k350.4k380.5k256.4k176.4k167.7k253.4k214.7k303.8k201.0k363.8k242.0k329.8k262.3k

Cost of goods sold

328.8k134.4k198.2k112.3k63.9k86.7k113.4k79.8k125.6k73.7k168.0k86.8k134.6k90.0k

Gross profit

18.8k215.9k182.3k144.1k112.5k81.0k140.0k134.9k178.1k127.3k195.8k155.3k195.2k172.3k

Gross profit Margin, %

5%62%48%56%64%48%55%63%59%63%54%64%59%66%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

171.7k9.9m16.3m10.4m5.1m4.1m6.2m20.2m18.3m

Accounts Receivable

92.6k69.8k64.4k15.6k21.1k24.1m

Prepaid Expenses

113.3k221.8k175.2k119.4k211.7k1.0m1.7m570.1k

Inventories

475.6k124.2k288.4k439.2k321.5k141.1k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

967.9k1.1m11.8m8.4m6.4m8.3m14.6m12.9m11.8m9.1m8.0m6.7m3.4m5.5m5.1m2.2m2.1m2.9m4.8m3.9m13.8m29.3m25.7m22.3m14.4m9.6m

Accounts Receivable

55.1k44.3k63.3k39.4k72.4k55.4k49.6k58.9k42.9k22.8k26.3k29.6k26.8k19.4k32.7k

Prepaid Expenses

168.3k123.9k152.3k236.4k210.5k302.4k227.0k154.4k144.6k221.6k133.8k90.4k173.3k192.9k111.8k171.9k106.3k517.7k769.6k722.6k1.3m1.7m1.7m355.4k555.5k328.7k295.5k

Inventories

500.6k465.5k363.0k353.8k279.9k117.3k303.0k223.3k265.9k239.0k263.9k377.0k364.1k299.3k241.5k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(7.7m)(13.1m)(16.1m)(5.8m)(11.7m)(7.0m)(6.7m)(9.9m)(15.6m)

Depreciation and Amortization

79.5k75.2k76.5k27.7k71.2k75.0k65.8k30.1k62.6k

Inventories

(209.0k)351.4k(164.2k)(150.8k)117.7k

Accounts Payable

225.3k(57.5k)(234.5k)(199.7k)331.1k446.0k525.8k225.3k498.1k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(3.9m)(5.7m)(1.6m)(8.5m)(11.1m)(1.6m)(3.7m)(13.0m)(1.6m)(3.5m)(4.6m)(1.3m)(7.6m)(9.5m)(2.1m)(2.4m)(4.3m)(2.0m)(3.2m)(5.3m)(2.1m)(4.4m)(7.2m)(3.3m)(8.1m)(12.0m)(5.2m)(17.5m)

Depreciation and Amortization

40.1k60.1k19.6k37.2k55.8k21.0k42.1k64.0k6.5k13.3k20.1k13.9k32.5k52.5k18.3k36.5k55.4k18.0k35.7k53.3k7.7k11.0k18.4k12.9k26.2k44.3k13.1k26.0k

Inventories

(233.9k)(198.8k)112.6k121.8k195.6k6.9k61.2k140.9k22.5k49.4k24.5k62.2k75.1k139.9k80.0k

Accounts Payable

96.4k29.0k11.7k1.7k(104.6k)(75.3k)64.9k(280.4k)(102.6k)(206.7k)(305.6k)(200.9k)(161.5k)51.6k17.0k(137.5k)(44.8k)(174.6k)(216.1k)317.2k293.4k719.1k548.5k931.8k697.7k851.4k245.3k(484.2k)
show all
USDQ2, 2011

Financial Leverage

-0.3 x
Show all financial metrics

Oragenics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

Learn more about about our premium products
SecurityScorecard logo

Oragenics Online and Social Media Presence

Oragenics's Trends

Embed Graph

Oragenics News and Updates

August 21, 2020

Thinking about buying stock in Oragenics Inc, Fortress Biotech, Super League Gaming, CleanSpark Inc, or iBio Inc?

NEW YORK, Aug. 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OGEN, FBIO, SLGG, CLSK, and IBIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
July 22, 2020

Thinking about buying stock in Oragenics Inc, Waitr Holdings, PDS Biotechnology, Novan Inc, or Ocugen Inc?

NEW YORK, July 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OGEN, WTRH, PDSB, NOVN, and OCGN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
July 10, 2020

Thinking about buying stock in WiMi Hologram Cloud, Oragenics Inc, Boeing, Matson Inc, or Cronos Group?

NEW YORK, July 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WIMI, OGEN, BA, MATX, and CRON. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
October 04, 2018

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oragenics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, Oct. 4, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Oragenics, Inc. (NYSE American: OGEN). If you...
October 03, 2018

Thinking about buying stock in DavidsTea, India Globalization Capital, Oragenics Inc, Stitch Fix or vTv Therapeutics?

NEW YORK, Oct. 3, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DTEA, IGC, OGEN, SFIX, and VTVT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Oragenics Blogs

May 04, 2020

Oragenics Announces New Member of the Board of Directors

Addition of Industry Veteran Bolsters Oragenics’ Focus on Vaccine Development TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), today announced that it has increased the size of its board of directors and appointed Ms. Kim Murphy to the board,…
May 04, 2020

Oragenics Acquires Noachis Terra Inc., To Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing “Spike Protein”

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), (the “Company” or “Oragenics”), today announced its acquisition of Noachis Terra Inc., following its entry into a stock purchase agreement (the “Stock Purchase Agreement”), to develop and commercialize TerraCoV2, a vaccine can…
February 07, 2020

Oragenics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of effective treatments for oral mucositis and new antibiotics against infectious diseases, announced today that Alan Joslyn, Ph.D., president and CEO of Oragenics, Inc., will present a corporate ov…
December 03, 2019

Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced that Alan Joslyn, Ph.D., president and CEO of Oragenics, Inc. will be a featured presenter…
December 02, 2019

Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced the completion of enrollment in its ongoing double-blind, randomized, placebo-controlled …
November 15, 2019

Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science Demonstrating First Complete Chemical Synthesis of Bicyclic Ring of a Mutacin 1140 Analog

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces the publication of the outcome of the a specific chemical synthesis of the bicyclic…
Show more

 Oragenics Frequently Asked Questions

  • When was Oragenics founded?

    Oragenics was founded in 1996.

  • Who are Oragenics key executives?

    Oragenics's key executives are Alan Joslyn, Charles L. Pope and Michael Sullivan.

  • How many employees does Oragenics have?

    Oragenics has 7 employees.

  • Who are Oragenics competitors?

    Competitors of Oragenics include PreBiomics, Izun Pharmaceuticals and N2 Biomedical.

  • Where is Oragenics headquarters?

    Oragenics headquarters is located at 4902 Eisenhower Blvd N #125, Tampa.

  • Where are Oragenics offices?

    Oragenics has an office in Tampa.

  • How many offices does Oragenics have?

    Oragenics has 1 office.